Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial

2020219 citationsJournal Articlebronze Open Access

Authors

Afferent Pharmaceuticals (acquired by Merck & Co., Inc., Kenilworth, NJ, USA).

Good health and well-being

Published in: The Lancet Respiratory Medicine

Volume 8, Issue 8, pp. 775-785

Field-Weighted Citation Impact: 21.39